0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast to 2030- Product Image
Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968659
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior decision-makers seeking actionable intelligence in biopharma, healthcare investment, and operational strategy will find the metabolic disorders therapeutics market offers both robust growth potential and significant transformation driven by clinical, regulatory, and supply chain innovation. Navigating these evolving dynamics is critical for leaders aiming to position their organizations for long-term advantage.

Market Snapshot: Metabolic Disorders Therapeutics Market

The Metabolic Disorders Therapeutics Market grew from USD 75.55 billion in 2024 to USD 81.80 billion in 2025. Market analysts project it will sustain an 8.38% CAGR to reach USD 122.49 billion by 2030. This expansion captures escalating global prevalence of metabolic conditions, technological advances in treatments, and diversification of end-user demand. The market’s trajectory reflects a blend of established pharmaceutical interventions and emerging precision medicine solutions.

Scope & Segmentation

This comprehensive report examines the global metabolic disorders therapeutics market across diverse categories, providing granular insights for strategic decision-making:

  • Treatment Classifications: Enzyme replacement therapies, gene therapies, medications and drugs, small molecule therapy
  • Disease Types: Diabetes mellitus (gestational, type 1, type 2), Gaucher’s disease, hemochromatosis, hypercholesterolemia, mitochondrial disorders, phenylketonuria (PKU), Pompe disease, thyroid disorders (hyperthyroidism, hypothyroidism), urea cycle disorders, Wilson's disease
  • Therapeutic Areas: Endocrine disorders, genetic disorders, nutritional disorders
  • Route of Administration: Intravenous, oral, subcutaneous
  • Patient Demographics: Adult, geriatric, pediatric patients
  • End User: Clinics, homecare settings, hospitals, specialty centers
  • Distribution Channel: Hospital pharmacies, online pharmacies, retail pharmacies
  • Regions Covered: Americas (USA, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (notable countries across Western Europe, Eastern Europe, Middle East, Africa), and Asia-Pacific (including China, India, Japan, Australia, South Korea, Southeast Asia)
  • Companies Profiled: Over 30 market leaders and innovators, such as Abbott Laboratories, AbbVie, Amgen, AstraZeneca, BioMarin, Novo Nordisk, Pfizer, Sanofi, Takeda, and others, representing diverse capabilities in research, manufacturing, and commercialization

Key Takeaways & Strategic Insights

  • The market is increasingly shaped by collaborative R&D, data-driven patient engagement, and integration of digital health platforms to support clinical outcomes and improve patient adherence.
  • Innovations in gene therapies and enzyme replacement treatments are shifting the standard of care for rare, hereditary, and chronic metabolic conditions, prompting portfolio diversification and specialized new entrants.
  • Regulatory flexibility—including expedited approval pathways and adaptive trial designs—is facilitating faster commercialization of novel therapeutics while increasing the importance of early compliance expertise.
  • Segment analysis reveals rising investment in non-invasive delivery technologies, with preferences evolving toward oral and subcutaneous therapies to support long-term disease management and better patient quality of life.
  • Channel diversification is yielding operational advantages, as online and direct-to-patient pharmacy models gain traction alongside traditional clinical and hospital routes.
  • Regional growth patterns highlight the importance of local manufacturing, adaptive reimbursement frameworks, and targeted clinician education to support both access and uptake.

Tariff Impact on Market Structure

The 2025 introduction of United States tariffs has influenced the cost structure for metabolic therapeutics. Manufacturers have adjusted by diversifying suppliers, creating local hubs, and renegotiating sourcing strategies to address increased import expenses on raw materials and active pharmaceutical ingredients. Enhanced scrutiny on pricing from healthcare payers and systems is driving an emphasis on manufacturing efficiency and value-driven pricing. Strategic localization and agile supply models are increasingly vital to maintain margin stability and continuity in research investment.

Methodology & Data Sources

This analysis leverages a rigorous mixed-methods approach. Data is sourced from peer-reviewed journals, regulatory filings, structured interviews with key industry stakeholders, and market intelligence databases. Quantitative findings are cross-validated through triangulation, while expert panels ensure the relevancy of qualitative insights and emerging trends. Thorough editorial review underpins report accuracy and reliability.

Why This Report Matters

  • Enables strategic investment decisions by delivering segment-level clarity and actionable market intelligence for leaders in pharmaceuticals, biotechnology, and healthcare delivery.
  • Supports operational agility by mapping the real impact of regulatory, technological, and trade dynamics across supply chains and clinical portfolios.
  • Equips stakeholders to anticipate and capitalize on emerging opportunities, ensuring readiness for evolving demands in the metabolic disorders therapeutics landscape.

Conclusion

This report provides a strategic roadmap for senior business leaders navigating the evolving metabolic disorders therapeutics market. Actionable insights and robust analysis empower organizations to drive growth, foster innovation, and enhance patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Metabolic Disorders Therapeutics Market, by Treatment Classifications
8.1. Introduction
8.2. Enzyme Replacement Therapies
8.3. Gene Therapies
8.4. Medications & Drugs
8.5. Small Molecule Therapy
9. Metabolic Disorders Therapeutics Market, by Disease Type
9.1. Introduction
9.2. Diabetes Mellitus
9.2.1. Gestational Diabetes
9.2.2. Type 1 Diabetes
9.2.3. Type 2 Diabetes
9.3. Gaucher’s Disease
9.4. Hemochromatosis
9.5. Hypercholesterolemia
9.6. Mitochondrial Disorders
9.7. Phenylketonuria (PKU)
9.8. Pompe Disease
9.9. Thyroid Disorders
9.9.1. Hyperthyroidism
9.9.2. Hypothyroidism
9.10. Urea Cycle Disorders
9.11. Wilson's Disease
10. Metabolic Disorders Therapeutics Market, by Therapeutic Areas
10.1. Introduction
10.2. Endocrine Disorders
10.3. Genetic Disorders
10.4. Nutritional Disorders
11. Metabolic Disorders Therapeutics Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Metabolic Disorders Therapeutics Market, by Patient Demographics
12.1. Introduction
12.2. Adult Patients
12.3. Geriatric Patients
12.4. Pediatric Patients
13. Metabolic Disorders Therapeutics Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Homecare Settings
13.4. Hospitals
13.5. Specialty Centers
14. Metabolic Disorders Therapeutics Market, by Distribution Channel
14.1. Introduction
14.2. Hospital Pharmacies
14.3. Online Pharmacies
14.4. Retail Pharmacies
15. Americas Metabolic Disorders Therapeutics Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Metabolic Disorders Therapeutics Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Metabolic Disorders Therapeutics Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. AbbVie Inc.
18.3.3. Acadia Pharmaceuticals Inc.
18.3.4. Amgen Inc.
18.3.5. Amicus Therapeutics, Inc.
18.3.6. Astellas Pharma Inc.
18.3.7. AstraZeneca plc
18.3.8. Bayer AG
18.3.9. Biocon Limited
18.3.10. BioMarin Pharmaceutical Inc.
18.3.11. Boehringer Ingelheim International GmbH
18.3.12. CHIESI Farmaceutici S.p.A.
18.3.13. Dr. Reddy’s Laboratories Ltd.
18.3.14. Eli Lilly and Company
18.3.15. F. Hoffmann-La Roche Ltd
18.3.16. GlaxoSmithKline PLC
18.3.17. Glenmark Pharmaceuticals Limited
18.3.18. Johnson & Johnson Services, Inc.
18.3.19. Lupin Limited
18.3.20. Luye Pharma Group Ltd
18.3.21. Merck & Co., Inc.
18.3.22. Novartis AG
18.3.23. Novo Nordisk A/S
18.3.24. Otsuka Holdings Co., Ltd.
18.3.25. Pfizer Inc.
18.3.26. Recordati Industria Chimica e Farmaceutica S.p.A
18.3.27. Sanofi S.A.
18.3.28. Sumitomo Pharma Co., Ltd.
18.3.29. Sun Pharmaceutical Industries
18.3.30. Takeda Pharmaceutical Company Limited
18.3.31. Teva Pharmaceutical Industries Ltd.
18.3.32. Torrent Pharmaceuticals Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. METABOLIC DISORDERS THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. METABOLIC DISORDERS THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. METABOLIC DISORDERS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 20. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY MEDICATIONS & DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GAUCHER’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEMOCHROMATOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY MITOCHONDRIAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PHENYLKETONURIA (PKU), BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY POMPE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY UREA CYCLE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY WILSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 71. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 72. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 73. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 74. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 75. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 77. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 81. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 126. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 127. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 128. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 129. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 130. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 132. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 135. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 136. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 137. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 138. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 139. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 141. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 153. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 154. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 155. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 156. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 157. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 159. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 162. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 163. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 164. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 165. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 166. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 168. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 173. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 174. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 175. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 182. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 183. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 184. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 191. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 192. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 193. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 195. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 198. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 199. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 200. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 201. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 202. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 204. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 209. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 210. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 211. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 213. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 216. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 217. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 218. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 219. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 220. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 222. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 225. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 226. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 227. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 228. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 229. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 231. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 236. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 237. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 238. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 240. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 246. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 247. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 248. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 249. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 252. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 253. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 254. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 255. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 256. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 258. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 261. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 262. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 263. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 264. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 265. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 267. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 279. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 280. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 281. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 282. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 283. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 285. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. POLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 288. POLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 289. POLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 290. POLAND METABOL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Metabolic Disorders Therapeutics market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Amgen Inc.
  • Amicus Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici S.p.A.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Recordati Industria Chimica e Farmaceutica S.p.A
  • Sanofi S.A.
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 81.8 Billion
Forecasted Market Value ( USD ) by 2030 $ 122.49 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Therapy, By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Therapy, By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
EUR$5,950USDGBP
Metabolic Disorder Therapeutics - Global Strategic Business Report - Product Image

Metabolic Disorder Therapeutics - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
EUR$5,850USDGBP
Metabolic Disorders Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Metabolic Disorders Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 186 Pages
  • Global
From
EUR$3,825USDGBP
EUR$4,500USDGBP
Peptide Based Metabolic Disorders Therapeutics Market Report 2025 - Product Image

Peptide Based Metabolic Disorders Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
EUR$4,490USDGBP
Amino Acid Metabolism Disorders Treatment Market by Treatment Type, Distribution Channel, End User, Product Type, Route of Administration, Patient Age Group - Global Forecast to 2030 - Product Image

Amino Acid Metabolism Disorders Treatment Market by Treatment Type, Distribution Channel, End User, Product Type, Route of Administration, Patient Age Group - Global Forecast to 2030

  • Report
  • 193 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP

About the Metabolic Disorder Drug Market

The Metabolic Disorder Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. It includes drugs used to treat metabolic disorders such as diabetes, obesity, and hyperlipidemia. These drugs are used to regulate the body's metabolism, which is the process of converting food into energy. Common drugs used to treat metabolic disorders include insulin, sulfonylureas, biguanides, thiazolidinediones, and GLP-1 agonists. These drugs are used to control blood sugar levels, reduce cholesterol, and promote weight loss. The Metabolic Disorder Drug market is highly competitive, with many companies offering a variety of drugs to treat metabolic disorders. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. Other companies in the market include Boehringer Ingelheim, Takeda, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more